Relmada Therapeutics (RLMD) Income towards Parent Company (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Income towards Parent Company data on file, last reported at -$56.4 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 216.54% year-over-year to -$56.4 million in Q1 2026; TTM through Mar 2026 was -$96.4 million, a 24.78% decrease from a year earlier, with the FY2025 full-year figure at -$64.6 million, up 19.72% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$56.4 million, down from -$20.0 million in the prior quarter.
• Over the last five years, Income towards Parent Company for RLMD reached as high as -$9.9 million in Q2 2025 and fell as low as -$56.4 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$27.7 million across 5 years, with a median of -$24.7 million in 2023.
• Across the five-year window, Income towards Parent Company surged 69.99% in 2022 and sank 216.54% in 2026, its largest moves.
• Year by year, Income towards Parent Company stood at -$39.1 million in 2022, then jumped by 34.58% to -$25.6 million in 2023, then increased by 27.91% to -$18.4 million in 2024, then slipped by 8.25% to -$20.0 million in 2025, then slumped by 182.54% to -$56.4 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$56.4 million in Q1 2026, -$20.0 million in Q4 2025, and -$10.1 million in Q3 2025.